Skip to main content
Top
Published in: Abdominal Radiology 5/2017

01-05-2017

Frequency of high blood glucose prior to FDG PET

Authors: Amir H. Khandani, Isabel M. Bravo, Parth S. Patel, Marijana Ivanovic, Deepa Kirk

Published in: Abdominal Radiology | Issue 5/2017

Login to get access

Abstract

Purpose

To assess the frequency of blood glucose level higher than 150 mg/dL in non-diabetic patients presenting for FDG PET.

Methods

We reviewed the electronic medical record (EMR) of all lymphoma patients who had at least one FDG PET/CT from July 1, 2014 through June 30, 2015. We extracted the blood glucose level at the time of the FDG PET during this 1-year time period and any previous PET scans these patients had. Patients’ diabetic status was determined from EMR.

Results

One hundred seventeen patients with 574 scans were included: 91 non-diabetic with 429 scans and 26 diabetic patients with 145 scans. Blood glucose level ranged from 44 to 259 mg/dL: 44 to 144 mg/dL in non-diabetic patients and 73 to 259 mg/dL in diabetic patients. There was no non-diabetic patient with a glucose level higher than 150 mg/dL at any occasion. Only one scan was performed with 144 mg/dL of glucose. All other scans were performed with a glucose level less than 140 mg/dL. There were nine diabetic patients with glucose level less than 150 mg/dL prior to all of their scans and 17 diabetic patients with a glucose level higher than 150 mg/dL prior to PET at least on one occasion.

Conclusions

In all non-diabetic patients, blood glucose level was below the lower limit of the recommended range prior to all their FDG PET scans while this was not the case in diabetic patients. We conclude that measuring blood glucose level prior to FDG PET may be limited to diabetic patients.
Literature
1.
go back to reference Delbeke D, Coleman RE, Guiberteau MJ, et al. (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47:885–895PubMed Delbeke D, Coleman RE, Guiberteau MJ, et al. (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47:885–895PubMed
3.
go back to reference Boellaard R, Delgado-Bolton R, Oyen WJ, et al. (2015) European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354CrossRef Boellaard R, Delgado-Bolton R, Oyen WJ, et al. (2015) European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354CrossRef
4.
go back to reference Graham MM, Badawi RD, Wahl RL (2011) Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med 52:311–317CrossRef Graham MM, Badawi RD, Wahl RL (2011) Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med 52:311–317CrossRef
5.
go back to reference American Diabetes Association (2016) Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes. Diabetes 39(Suppl 1):S13–S22 American Diabetes Association (2016) Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes. Diabetes 39(Suppl 1):S13–S22
6.
go back to reference Mirpour S, Meteesatien P, Khandani AH (2012) Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT? Rev Esp Med Nucl Imagen Mol 31:71–77PubMed Mirpour S, Meteesatien P, Khandani AH (2012) Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT? Rev Esp Med Nucl Imagen Mol 31:71–77PubMed
7.
go back to reference Hara T, Higashi T, Nakamoto Y, et al. (2009) Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for 305 clinical oncologic imaging? Ann Nucl Med 23:657–669CrossRef Hara T, Higashi T, Nakamoto Y, et al. (2009) Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for 305 clinical oncologic imaging? Ann Nucl Med 23:657–669CrossRef
8.
go back to reference Rabkin Z, Israel O, Keidar Z (2010) Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med 51:1015–1120CrossRef Rabkin Z, Israel O, Keidar Z (2010) Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med 51:1015–1120CrossRef
Metadata
Title
Frequency of high blood glucose prior to FDG PET
Authors
Amir H. Khandani
Isabel M. Bravo
Parth S. Patel
Marijana Ivanovic
Deepa Kirk
Publication date
01-05-2017
Publisher
Springer US
Published in
Abdominal Radiology / Issue 5/2017
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-1013-3

Other articles of this Issue 5/2017

Abdominal Radiology 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.